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Abstract 
Background 
The underlying mechanisms limiting exercise capacity in patients with heart failure and preserved 
ejection fraction (HFpEF) are not fully understood.  
Objectives 
We sought to discern which central (e.g. heart rate, stroke volume, filling pressure) and peripheral 
factors (e.g. O2 utilization by skeletal muscle, BMI) during exercise were most strongly associated 
with the presence of HFpEF as compared to healthy controls exercising at the same workload. 
Methods 
In HFpEF (n=108) patients, we measured the hemodynamic response at peak exercise using right 
heart catheterization, and compared it with healthy controls (n=42) at matched workloads, to reveal 
hemodynamic differences that were not attributable to the workload performed. The populations 
studied were prospectively included in REDUCE-LAP HF trials and HemReX study. Univariable 
and multivariable logistic regression models were used to analyze variables associated with HFpEF 
vs. controls.  
Results 
Compared with healthy controls, pulmonary capillary wedge pressure (PCWP) and stroke volume 
(SV), were the only independent hemodynamic variables that were associated with HFpEF, 
explaining 66% (p<0.0001) of the difference between groups. When relevant baseline 
characteristics were added to the base model, only BMI emerged as an additional independent 
variable, in total explaining of 90% of the differences between groups (p<0.0001); PCWP (47%), 
BMI (31%), SV (12%).  
Conclusion 
We identified 3 key variables (PCWP, BMI, and SV, respectively) that independently correlate with 
the presence of HFpEF patients compared to healthy controls exercising at the same workload. 
Therapies that decrease left heart filling pressures could improve exercise capacity, and possibly 
prognosis.  
 
Condensed abstract 
Background and objectives 
We sought to discern which factors during exercise that were associated with the presence of 
HFpEF as compared to healthy controls. 
Methods 
In HFpEF (n=108) patients, we measured the hemodynamic response at peak exercise and 
compared it with healthy controls (n=42) at matched workloads.  
Results 
Pulmonary capillary wedge pressure (PCWP), BMI, and stroke volume (SV), were the only 
independent hemodynamic variables that were associated with HFpEF, explaining 90% (p<0.0001) 
of the difference between groups.  
Conclusion 
Therapies that decrease left heart filling pressures could improve exercise capacity, and possibly 
prognosis.  
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Abreviations list 
BMI – body mass index 
Ca-vO2 – arterio-venous oxygen difference 
CVP – central venous pressure 
CI – cardiac index 
CO – cardiac output 
HFpEF – heart failure with preserved ejection fraction 
mPAP – mean pulmonary pressure 
PCWP – pulmonary capillary wedge pressure 
PVR – pulmonary vascular resistance 
SVR – systemic vascular resistance 
VO2-max – maximal oxygen consumption 
 
Introduction 
A hallmark of heart failure with preserved ejection fraction (HFpEF) is severely impaired exercise 
capacity. Exercise intolerance, manifested by symptoms of exertional dyspnea and fatigue, impairs 
quality-of-life and is therefore a key patient-centered outcome in HFpEF. In addition, reduced 
exercise capacity in HFpEF is associated with worse clinical outcomes(1, 2).   However, the 
underlying mechanisms limiting exercise capacity in HFpEF patients remain incompletely 
understood(3).  The studies performed to date have used a variety of techniques to examine 
mechanisms of exercise intolerance in HFpEF, and have variably reported contributions of central 
factors (e.g. heart rate, stroke volume, filling pressures) and peripheral factors (e.g. O2 utilization 
by skeletal muscle, BMI, renal function), but only a few have directly analyzed the relationships 
between symptoms and aerobic capacity using gold-standard invasive measures(4–6). Importantly, 
no study to date has included a control population exercising at the matched workload to the peak 
level of HFpEF.  
In order to fill this critical knowledge gap, we performed a study with invasive exercise tests, using 
data from 3 of the largest prospective trials of HFpEF patients and healthy participants (n=150)(7–
9). Importantly, the healthy controls were prospectively enrolled and rigorously screened to verify 
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the absence of cardiac disease. To discern which central and peripheral factors that were 
independently associated with HFpEF patients compared to healthy controls, we performed two 
complementary analyses: we compared the hemodynamic response of HFpEF patients at their peak 
exercise workload capacity to that of controls exercising at the same workload to reveal 
hemodynamic differences, not attributable to the workload performed. In a supplemental analysis 
the hemodynamic response during peak exercise in both HFpEF patients and controls were 
compared relative to the individual workloads achieved.  
 
 
Methods 
This study used baseline data from 2 trials and one population study; Reduce Elevated Left Atrial 
Pressure in Patients With Heart Failure (REDUCE LAP-HF) trial, REDUCE LAP-HF I trial, and 
The Effect of Age on the Hemodynamic Response During Rest and Exercise in Healthy Humans 
(HemReX) study. Patients and healthy participants were recruited 2013-2016. All participants 
provided oral and written informed consent prior to enrollment. All studies were approved by 
relevant ethical committees and respected the Helsinki Declaration. The primary findings of the 
studies have been published(7–9).  All measurements from HFpEF patients were obtained prior to 
InterAtrial Shunt Device (IASD) implantation.  
HFpEF population  
In summary, patients with elevated pulmonary capillary wedge pressure (PCWP) either at rest or 
during exercise, and signs and symptoms of HF were included in two studies evaluating an IASD 
(IASD system II, Corvia Medical, Inc. [Tewksbury, MA, USA]) (REDUCE LAP-HF: 
nonrandomized, open-label design. REDUCE LAP-HF I: randomized, double-blinded design). The 
primary objective of the trials was to assess the safety and efficacy of IASD implantation. Key 
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inclusion criteria were: informed consent, NYHA class II-IV, LVEF≥40% determined by 
echocardiography, ≥ 1 HF hospitalization within last 12 months prior to screening and/or elevated 
natriuretic peptides, age ≥ 40 years, elevated left ventricular filling pressures with a gradient 
compared to central venous pressure (CVP) documented by ≥1 of the following [end-expiratory 
PCWP or LVEDP at rest ≥15 mmHg and greater than CVP] and/or PCWP during supine bike 
exercise ≥25 mmHg. Key exclusion criteria were: cardiac index ≤2.0 l/min/m2, obstructive or 
restrictive cardiomyopathy, moderate-severe heart valve disease, atrial fibrillation with resting heart 
rate >100 beats/min and dialysis or eGFR <25 ml/min/1.73m2.  As the inclusion criteria and the 
invasive protocol were similar, data was pooled from the two studies. Additional details on the trial 
designs have been published(10, 11).  
Healthy population 
Sixty-two healthy subjects aged 20-80 were enrolled in the primary prospective study, however 
only patients aged ≥40 years were included in the present study (n=42), as this cutoff corresponded 
to the age inclusion criteria for the HFpEF studies. Healthy subjects were deemed eligible if they 
fulfilled inclusion criteria; free from history of any acute or chronic cardiac or pulmonary disease; 
echocardiography without signs of chamber hypertrophy, reduced left ventricular (LV) ejection 
fraction or significant valvular disease; normal spirometry for their age; routine blood chemistry test 
with normal values (including NT-proBNP); BMI 20-30 kg/m2; and an exercise test with ECG 
without any pathological findings. Additional details on study design have been published(9). 
The protocols of all 3 trials were published on clinicaltrials.gov (NCT01913613, NCT02600234, 
NCT01974557) before subject enrollment. 
Baseline data 
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Each subject underwent transthoracic echocardiography (TTE) performed according to 
echocardiographic and core laboratory standards at baseline. Blood samples were collected and 
analyzed according to standards used at each participating site.  
Hemodynamic parameters 
Hemodynamic variables were measured at rest and during ergometer exercise in the supine position 
in both HFpEF patients and healthy participants. Ergometer resistance was increased every 3-4 
minutes with increments of either 20 watt (HFpEF) or 25 watt (controls) until maximal effort was 
achieved. In HFpEF patients, maximal effort/peak exercise was judged by patients and physicians, 
when patients were not able to maintain 60 revolutions per minute on the ergometer at a given 
workload. In healthy participants, maximal effort was defined as 4 minutes of exercise in a supine 
ergometer with lactate buildup and objective signs of severe exertion at a workload corresponding 
to 75% of VO2-max identified during a previous test on an upright ergometer, in accordance with 
the lower VO2-max achievable in a supine compared to an upright position(4). A Swan-Ganz 
catheter was positioned in the pulmonary artery via the internal jugular or brachial vein. For all 
signals, 10 second segments were recorded.  Signals were quantified by visual estimation of values 
at end-expiration.  At rest, multiple beats (>3) were typically available, but often this was not the 
case during exercise with higher ventilatory frequency. 
The following hemodynamic data were collected; CVP, mean pulmonary artery pressure (mPAP), 
PCWP, cardiac output using thermodilution technique (CO), non-invasive systolic blood pressure 
(SBP), non-invasive diastolic blood pressure (DBP), non-invasive peripheral oxygen saturation 
(SaO2), and heart rate (HR). In addition, mixed venous oxygen (SvO2) was sampled from the 
pulmonary artery.  
Derived variables 
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Systemic vascular resistance (SVR) was calculated as 80 x (MAP – CVP)/CO. Pulmonary vascular 
resistance (PVR) in Wood units was calculated as (mPAP - PCWP)/CO. Transmural pressure 
(TMP) was calculated as PCWP – RAP. Transpulmonary gradient (TPG) was calculated as mPAP-
PCWP. Cardiac index (CI) was calculated as CO/body surface area (BSA). Stroke volume, indexed 
was calculated as CI/heart rate (HR). The venous blood oxygen content (CvO2) was calculated 
using the formula(6): 𝐶𝑣𝑂2 =  ℎ𝑒𝑚𝑜𝑔𝑙𝑜𝑏𝑖𝑛 (
𝑔
𝑑𝐿
) × 1.39 × 𝑆𝑣𝑂2. Arterial oxygen content was 
calculated likewise using either non-invasively measured arterial saturation or imputed based on the 
median value if missing (46%). We did not account for plasma-bound oxygen, as we did not have 
data on partial pressures. However, this component contributes very little to oxygen content given 
that measurements are made close to sea level, and that patients do not suffer from grave anemia. 
Peripheral arterio-venous difference was calculated as the difference in blood oxygen content; Ca-
vO2 = CaO2-CvO2. 
Statistics 
Data was summarized using mean±SD, except NT-proBNP which was summarized as median 
[IQR]. Student’s t-test and Wilcoxon rank-sum test was used to test for differences between groups. 
A sensitivity analysis excluding patients with BMI >30 kg/m2 and adjustments for BMI (and age) 
were performed, as this was a pre-defined exclusion criterion for the control group. As 
hemodynamic measurements were obtained at several sub-maximal exercise workloads in healthy 
controls compared to peak exercise only in HFpEF, data obtained at various workloads from a 
single control patient could be included more than once in the matched workload analysis (72 
workload entries from 42 patients). Hemodynamic data from the control group obtained at 
workloads higher than maximally achieved by the HFpEF patients was omitted in the matched 
workload analysis. In the relative workload analysis, peak workloads were used in both groups. 
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Univariable and multivariable logistic regression models were used to analyze variables associated 
with HFpEF vs. controls, ie. the dichotomous dependent variable was the HFpEF. As individual 
patients could contribute with data from more than one workload, standard errors were estimated 
using patient-level clustering in regression models (matched workload analysis). Significant 
independent variables were identified using stepwise selection (p<0.05). To minimize collinearity 
issues no derived variables or indexed variables were included in the models. Mean pulmonary 
pressure and PCWP were collinear, and only PCWP was used for modeling. Both hemodynamic 
measures and clinical variables listed in Table 1 were included in the models except VO2-max and 
NT-proBNP due to collinearity and missing data, respectively. Furthermore, NYHA class, 
echocardiographic abnormalities, and medications were omitted, as these measures were not present 
in the healthy controls by definition.  
Dominance analysis was used to obtain the proportion of fit metric which was attributable to each 
independent variable as described by Azen et al.(12) (STATA package domin). This analysis 
aggregates results across multiple models, whereby the cumulative contributions of independent 
variables may differ slightly from the r2 values. A p value of 0.05 was considered statistically 
significant. All analyses were conducted using STATA version 14 (College Station, TX). 
 
 
Results 
Patients with HFpEF from the REDUCE-LAP HF(7) (n=64) and REDUCE-LAP HF I(8) (n=44) 
trials were included and compared with healthy controls from the HemReX study(9) (n=42).. 
Baseline characteristics and hemodynamic variables at rest are summarized in Tables 1 & 2. All 
variables were significantly different between controls and HFpEF at rest except; gender, SBP, left 
ventricular end-diastolic volume (LVEDVi), EA ratio, MAP, SV, SVi, CO, CI, SVR, PVR, and Ca-
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vO2. Limiting comparisons to patients (n=33) and controls (n=42) with BMI ≤ 30 kg/m2, the same 
differences between groups were noted, except for BMI, BSA, SV, SVI, and HR which were 
statistically similar between groups, while EA ratio and PVR were higher and CO was lower in 
HFpEF compared to controls (see tables S1-2, Supplemental material). Patients grouped according 
to LVEF above or below 50%, had comparable baseline characteristics (see table S3). 
 
 
Central and peripheral exercise factors at matched workloads 
The maximal workload achieved by HFpEF patients was 43±18 W. The matched mean workload of 
the control group was 45±22 W (p=0.41 for difference between HFpEF [n=107] vs. controls 
[n=72]). See Table 2 for hemodynamic data at matched workloads. The following changes from 
baseline to matched workload in HFpEF vs controls were observed; Heart rate (+29±19 vs. +29±16 
bpm, p=0.94), Cardiac output (+3.1±1.9 vs. +5.4±2.0 l/min, p<0.0001), Cardiac index (+1.5±0.9 
vs. +2.9±1.1 l/min/m2, p<0.0001), stroke volume (+8±21 vs. +35±20 ml, p<0.0001), stroke volume 
[indexed] (+4±10 vs. +19±10 ml/m2, p<0.0001), arterio-venous oxygen difference [Ca-vO2] 
(+3.7±2.5 vs. +4.9±1.5 ml/dl, p=0.0004), and systemic vascular resistance (-367±365 vs. -716±234 
dyne x s/cm5, p<0.0001),  Figure 1. 
 
Variables associated with HFpEF during exercise at matched workloads 
Hemodynamic variables associated with HFpEF during matched workloads are shown in Table 3.  
When relevant baseline variables from table 1 were added to the base model of hemodynamic 
variables during matched exercise, BMI was the only additional independent variable. BMI 
increased the r2 value of the model from 0.66 to 0.90. The individual contributions of each 
independent variable are shown in figure 2.  
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In a sensitivity analysis limited to controls and patients with BMI ≤30 kg/m2, the results were 
similar with regard to both the independent hemodynamic variables identified (PCWP and SV), as 
well as the coefficients (table S4, Supplemental material).  
 
Central and peripheral exercise factors at peak exercise 
The mean peak workload achieved was 45±13 vs. 137±35 W, p<0.0001 for HFpEF vs. controls.  
Heart rate increased from baseline to peak exercise +29±19 vs. +64±19 bpm, p<0.0001 for HFpEF 
vs. controls. In the HFpEF group, there was no effect of beta blocker use (p=0.14) or atrial 
fibrillation (p=0.88) on peak exercise heart rate, but progressive age was associated with lower 
heart rate at peak exercise (p=0.01).  
Cardiac index increased +1.5±0.9 vs. +5.8±1.4 l/min/m2, p<0.0001, and stroke volume (indexed) 
increased +4±10 vs. +26±16 ml/m2, p<0.0001 for HFpEF vs. controls. 
At peak exercise, arterio-venous oxygen difference (Ca-vO2) was significantly lower in HFpEF 
patients 9.1±2.9 vs. controls 12.8±1.3 ml/dl, p<0.0001. Systemic vascular resistance decreased -
359±371 vs. -904±280 dyne x s/cm5, p<0.0001 for HFpEF vs controls. 
 
Comparison of central and peripheral exercise factors relative to workload 
All hemodynamic variables examined differed significantly between controls and HFpEF patients at 
peak exercise, except mean arterial pressure (Table 4). In univariable analyses, all workload 
corrected hemodynamic variables were individually associated with the HFpEF phenotype (Table 
5). When multivariable analysis was performed with hemodynamic variables, only workload 
corrected PCWP was independently associated with the presence of HFpEF, explaining 87% of the 
variability (p<0.0001). A supplementary multivariable analysis using workload corrected heart rate 
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reserve (baseline to peak exercise in both groups), did not show that heart rate was significant 
(p=0.17, data not shown).   
When the model was adjusted for BMI and age, workload corrected PCWP was still the biggest 
contributor to the HFpEF phenotype; PCWP/workload (64%), BMI (21%), age (10%).  
 
Discussion 
Our objective was to determine the factors that contribute most strongly to the presence of HFpEF, 
a cohort for whom exercise capacity is profoundly impaired. Our study is the first to compare 
hemodynamic responses in HFpEF patients during their peak levels of exercise to those of healthy 
controls at the same matched workload, thereby enabling determination of which hemodynamic 
differences were specific to the HFpEF phenotype rather than being attributable to differences in 
workload achieved at peak exercise. A supplemental analysis of hemodynamics responses relative 
to workload at peak exercise for both groups was also performed. 
At matched workloads, we identified 2 hemodynamic variables - PCWP and SV - and 
1 anthropometric variable – BMI - that independently contributed to the HFpEF phenotype.  Among 
these factors, the strongest was increased PCWP (47%). Together these variables accounted for 
66% (without BMI) and 90% (with BMI) of the difference between HFpEF and controls. These 
findings were supported by analysis of hemodynamic changes relative to workload during peak 
exercise.   
 
Exercise-limiting factors in HFpEF at matched workloads 
The HFpEF patients had a similar absolute increase in heart rate compared to controls, 
but modestly higher peak heart rate at similar workloads. Our finding that heart rate response did 
not appear abnormal in HFpEF is at variance with some prior studies, particularly those where 
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exercise was performed in the upright position(13, 14), but is in agreement with others(15–17). 
Although our analyses did not show any association between the presence of HFpEF and heart rate 
at matched workload, this does not mean that modulating heart rate will not increase exercise 
capacity. In this study heart rate was markedly lower at peak exercise in HFpEF compared to 
healthy, which is a consistent finding in other HFpEF studies(18), and has led to studies 
investigating whether atrial pacing improves exercise capacity in this cohort [NCT02145351](19).   
At matched workloads, cardiac index was lower in HFpEF compared to controls, which was due to 
an inability to increase stroke volume during exercise, despite both groups having comparable 
stroke volumes at rest. This observation is similar to findings at matched lower-level workload 
(20W) observed in prior studies(17, 20).  Importantly, whereas the limitation in exercise capacity in 
healthy persons is primarily governed by highest cardiac output achievable(9), the limiting factor(s) 
in HFpEF patients may be multifactorial, and not necessarily limited by cardiac output. Hence, in 
these patients, maximal exertion may be reached before their maximal uptake in oxygen.
 PCWP showed dramatic increases during exercise leading to a high PCWP:CO ratio 
in HFpEF patients. The current data confirms and extends upon prior studies showing that higher 
PCWP at peak exercise is associated with more impaired myocardial function(17), greater symptom 
severity(5), and worse aerobic capacity(4, 5) in HFpEF. We also observed that arterio-venous 
oxygen difference (Ca-vO2) was significantly reduced in HFpEF patients compared to controls, as 
previously reported by some groups(6, 21, 22). The current data are unique in that Ca-vO2 was 
impaired in HFpEF compared to controls even at submaximal workload, which differs from 2 other 
studies that showed higher Ca-vO2 during lower workloads in HFpEF(17, 23). These data provide 
further support for the hypothesis that reduced oxygen extraction and utilization in skeletal muscle 
may be an important determinant of functional limitation in HFpEF(6, 24), however our study 
design did not allow us to further describe the mechanisms of peripheral oxygen utilization 
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 When assessing which hemodynamic variables were independently associated with 
HFpEF, only 2 central factors were statistically significant: PCWP (61%), and SV (8%). This 
suggests that high left heart filling pressure is a key contributor to exercise intolerance in HFpEF, in 
agreement with other studies(4, 5, 17). When baseline characteristics were added to the model, BMI 
was also a significant independent contributor. Thus just 3 variables (PCWP, BMI, and SV) 
explained 90% of the variability between HFpEF and control group designation. In a sensitivity 
analyses limited to patients with BMI ≤30 kg/m2 (where BMI was similar between groups), PCWP 
and SV remained the sole independent variables associated with the exercise limitation in HFpEF 
(Table S3, Supplemental material).  
Previous studies have shown hemodynamic impairments in HFpEF relative to controls 
at lower matched submaximal workloads(17, 20, 25), but this is the first study to show 
hemodynamic deficits in HFpEF at their individual peak workload when matched to the same 
workload as controls. This provides compelling evidence supporting the importance of abnormal 
hemodynamics, in particular left heart filling pressures, in the pathophysiology of exercise 
intolerance in HFpEF.  
Our finding of a strong association with BMI and reduced exercise capacity in HFpEF 
is in accord with other recent reports(26, 27), including a recent study showing that BMI was 
strongly associated to NYHA class in HFpEF patients(28). Excess adipose tissue can contribute to 
HFpEF pathophysiology via a range of adverse effects, including systemic inflammation, capillary 
rarefaction in cardiac and skeletal muscle, and impaired skeletal muscle perfusion and 
mitochondrial function(26, 29, 30). The causal association between excess adipose tissue and 
exercise capacity in HFpEF patients is further supported by data from Kitzman et al. who 
demonstrated that caloric restriction in overweight HFpEF patients significantly increased their 
exercise capacity (VO2-max) in proportion to reduced fat mass and increased percent lean mass(30). 
15 
 
Importantly, in our study PCWP was associated with HFpEF independent of BMI. This finding is in 
agreement with recent data showing that ventilatory abnormalities and dyspnea in HFpEF patients 
are related to PCWP even after accounting for the effects of BMI(5). 
 
Exercise limiting factors in HFpEF at relative workloads 
As expected, the healthy control group was able to work at considerably higher workloads 
compared with the HFpEF patients. As changes in hemodynamics are not necessarily proportional 
to the workload performed(9, 17), this could potentially introduce a bias in the matched workload 
analyses as the two groups performed different relative workloads (max vs. sub-max workload). 
Hence, we performed a complementary analysis using changes relative to the workload performed 
at peak exercise for both groups.  
Although all workload corrected hemodynamic variables were individually associated 
with the HFpEF phenotype during exercise, the only independent variable was PCWP/workload (r2: 
0.87). BMI was also significantly associated with the difference between HFpEF and controls, 
increasing the r2 modestly to 0.94. This analysis further supports that increased left heart filling 
pressures is a major determinant of the exercise associated limitation experienced by HFpEF 
patients.  
Strengths and Limitations 
Our study included a large number of well-characterized HFpEF patients and healthy controls 
enrolled across 3 continents, with comprehensive invasive hemodynamic measurements performed 
at rest and during exercise. We uniquely compared the hemodynamic response at peak exertion in 
HFpEF patients with healthy controls at a similar workload, thereby elucidating the most significant 
differences between these groups. Furthermore, we prospectively included both HFpEF patients and 
actively screened controls ensuring healthy individuals (see table 6 for a comparison with earlier 
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studies). However, there are limitations: 1) Peak exercise was determined differently between 
patients and controls. However, this would not have affected the results of the matched workload 
analysis. 2) Our healthy controls were selected to have a BMI between 20-30 kg/m2, whereas no 
BMI limit was imposed on the HFpEF patients as multiple population studies have shown HFpEF 
patients in general tend to be overweight/obese(26). To account for this potential bias, we adjusted 
for BMI, and performed sensitivity analysis restricted to patients with BMI ≤30 kg/m2, which 
confirmed the primary study findings 3) Some features of our study design may have minimized the 
potential contribution of heart rate to reduced exercise capacity. Since heart rate is linearly and 
tightly related to workload, matching workloads tend to minimize heart rate differences. However, 
our relative workload analysis likely decreased this potential bias. 4) Activities of daily living 
during which patients experience their exertional symptoms are usually performed in the upright 
position, but we performed exercise testing in the supine position because it facilitated use of 
invasive measurements which was critical to assess the role of hemodynamic measures. 
Nevertheless, since patients and controls performed protocols in similar position, this should not 
have substantial effects on intergroup differences. 5) As in other studies, our conclusions are based 
on group averages.  However, as shown recently by Houstis et al., mechanisms of exercise 
intolerance in HFpEF are likely multi-factorial, and may vary significantly between patients(22). 6) 
Our HFpEF inclusion criteria were based on invasive measurements, not least PCWP. These criteria 
differ from HF guidelines, that use surrogate markers for increased left heart filling pressure (e.g. 
increased left atrium, elevated natriuretic peptides), and hence our cohort studied may differ from 
HFpEF populations diagnosed using current guidelines. This may also have confounded the 
findings towards hemodynamic measures.   
Conclusion 
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In this large group of patients and healthy controls who underwent invasive exercise testing, we 
identified 3 key variables (PCWP, BMI, and SV, respectively) that independently contributed to the 
reduced exercise capacity in HFpEF patients compared to healthy controls during supine exercise at 
matched workloads. Together, these variables explained 90% of the difference between HFpEF and 
controls, and among these, PCWP was the strongest contributor. These findings suggest the 
potential for interventions that alleviate high left heart filling pressure during exercise to improve 
the key outcome of exercise intolerance in HFpEF patients.   
 
 
Competency in Medical Knowledge 
Patients with HFpEF experience limited functional capacity, high left heart filling pressures, and 
generally many comorbid conditions. The most significant differences between HFpEF patients and 
healthy controls performing the same workload are increased PCWP, lower SV, and a higher BMI. 
 
Translational Outlook 
Especially increased left heart filling pressures are associated with differences between HFpEF 
patients and healthy, indicating that therapies aimed at reducing PCWP could result in improved 
exercise capacity for HFpEF patients. 
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Table 1. Patient characteristics. 
 
Controls (n=42) HFpEF (n=108) p-value 
Age 59±11 70±8 <0.0001 
Sex (females) 22/20 (52% females) 64/44 (59% females)  0.44 
Weight (kg) 76±11 94±22 <0.0001 
BMI (kg/m2) 25±3 34±7 <0.0001 
BSA (m2) 1.90±0.17 2.01±0.25 0.01 
Medical history    
Atrial fibrillation 0 45 (42%) <0.0001 
COPD 0 16 (15%) <0.0001 
Diabetes 0 46 (43%) <0.0001 
NYHA class   <0.0001 
2 N/A 18 (17%)  
3 N/A 89 (82%)  
4 N/A 1 (1%)  
Systolic BP 138±16 138±23 0.97 
Diastolic BP 79±9 71±14 0.003 
VO2-max (ml/min) 2436±661 1381±509 <0.0001 
VO2-max (ml/kg/min) 32±7 16±4 <0.0001 
RER (VO2:VCO2) 1.10±0.06 1.04±0.09 0.01 
eGFR (ml/min/1.73m2) 76±13 57±21 <0.0001 
Hemoglobin (g/dl) 14±1 13±2 <0.0001 
NT-proBNP (pg/ml) 59 [50, 120] 390 [218, 941] <0.0001 
Echocardiography    
LVEF (%) 62±7 52±10 <0.0001 
LVEDVi (ml/m2) 70±16 69±21 0.72 
LAi (ml/m2) 23±8 39±22 <0.0001 
EA 1.2±0.4 1.5±1.2 0.11 
E/e’ 9±3 15±6 <0.0001 
TAPSE (cm) 2.6±0.4 2.0±0.5 <0.0001 
Medication    
Betablocker use 0 81 (84%) <0.0001 
ACE/A2RA 0 68 (76%) <0.0001 
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Table 2. Hemodynamic variables at rest and during exercise at matched workloads. 
 
Baseline (rest)  Exercise (matched workloads)  
 
 
Controls (n=42) HFpEF (n=108) p-value Controls (n=72) HFpEF (n=107) p-value Adjusted p-value* 
Workload (watt) 0 0 - 45±22 43±18 0.41 0.57 
Heart rate (bpm) 63±9 70±14 0.005 93±18 99±20 0.04 0.03 
MAP (mmHg) 93±9 93±14 0.96 99±14 111±23 0.0007 0.17 
SV (ml) 83±21 82±30 0.85 115±31 90±29 <0.0001 <0.0001 
SVi (ml/m2) 43±8 41±13 0.24 60±13 44±12 <0.0001 N/A 
CO (l/min) 5.1±1.0 5.6±2.0 0.12 10.5±2.3 8.7±3.0 <0.0001 <0.0001 
CI (l/min/m2) 2.7±0.4 2.8±0.8 0.48 5.6±1.1 4.3±1.2 <0.0001 N/A 
RAP (mmHg) 5±2 9±3 <0.0001 10±4 19±6 <0.0001 <0.0001 
mPAP (mmHg) 15±3 26±8 <0.0001 30±8 46±11 <0.0001 <0.0001 
PCWP (mmHg) 9±3 19±6 <0.0001 19±7 35±7 <0.0001 <0.0001 
SVR (dyne x s/cm5) 1437±281 1329±415 0.13 712±182 941±355 <0.0001 <0.0001 
PVR (Wood) 1.2±0.5 1.5±0.9 0.08 1.12±0.50 1.44±1.23 0.05 0.77 
TPG (mmHg) 6±2 8±4 0.02 11±4 11±8 0.52 0.005 
TMG (mmHg) 3±2 9±5 <0.0001 9±4 16±7 <0.0001 <0.0001 
CaO2 (ml/dl) 19.6±1.7 17.1±2.6 <0.0001 19.2±1.5 16.7±2.7 <0.0001 0.56 
CvO2 (ml/dl) 14.9±1.7 12.1±2.2 <0.0001 9.6±2.0 8.1±2.8 0.0001 0.004 
Ca-vO2 (ml/dl) 4.8±0.8 5.1±1.3 0.19 9.6±1.6 8.6±2.8 0.01 0.02 
Data obtained at various workloads from a single control patient could be included more than once in the 
matched workload analysis accounting for the difference in n in the Control group (n=43 vs. 72). One HFpEF 
patient did not manage to perform exercise, accounting for the difference in (n=108 vs. 107). *Adjusted for 
age and BMI (except indexed variables).  
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Table 3. Hemodynamic variables associated with HFpEF at matched workloads. 
 
Univariable   
Multivariable 
Model 1  
(R2:0.66, p<0.001) 
 
Multivariable 
Model 1  
(R2:0.92, p=0.15) 
 
 
Coefficient p-value  Coefficient p-value Coefficient p-value 
Age (Y) 0.1 (0.1, 0.1) <0.001    0.1 (-0.0, 0.3) 0.14 
BMI (kg/m2) 0.4 (0.3, 0.5) <0.001    2.3 (0.3, 4.2) 0.02 
Heart rate (bpm) 0.02 (0.00, 0.03) 0.04      
MAP (mmHg) 0.03 (0.01, 0.05) 0.001      
SV (ml/m2) -0.03 (-0.04, -0.01) <0.0001  -0.04 (-0.06, -0.01) 0.001 -0.24 (-0.44, -0.04) 0.02 
RAP (mmHg) 0.4 (0.3, 0.5) <0.0001      
PCWP (mmHg) 0.4 (0.3, 0.5) <0.0001  0.4 (0.2, 0.6) <0.0001 0.9 (0.2, 1.5) 0.01 
Ca-vO2 (ml/dl) -0.2 (-0.3, -0.0) 0.01      
SVi (ml/m2) -0.11 (-0.14, -0.07) <0.0001      
CO (l/min) -0.23 (-0.36, -0.10) 0.001      
CI (l/min/m2) -0.90 (-1.19, -0.62) <0.0001      
mPAP (mmHg) 0.2 (0.1, 0.3) <0.0001      
SVR (dyne x s/cm5) 0.003 (0.001, 0.004) <0.0001      
PVR (Wood) 0.4 (-0.0, 0.7) 0.06      
Model 1: HR, MAP, SV, RAP, PCWP, and Ca-v02 were included in the model. 
Model 2: HR, MAP, SV, RAP, PCWP, and Ca-v02 (Model 1), adjusted for BMI and age. 
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Table 4. Hemodynamic variables at peak exercise. 
 Controls (n=42) HFpEF (n=107) p-value 
Workload (watt) 137 ± 35 43 ± 18  <0.001 
Heart rate (bpm) 127 ± 18 99 ± 20 <0.001 
MAP (mmHg) 111 ± 16 111 ± 23 0.96  
SV (ml) 129 ± 33 90 ± 29 <0.001 
SVi (ml/m2) 68 ± 15 44 ± 12 <0.001 
CO (l/min) 16 ± 3 9 ± 3 <0.001 
CI (l/min/m2) 8.4 ± 1.3 4.3 ± 1.2 <0.001 
RAP (mmHg) 10 ± 5 19 ± 5.5 <0.001 
mPAP (mmHg) 36 ± 10 46 ± 11 <0.001 
PCWP (mmHg) 21 ± 8 35 ± 7 <0.001 
TMP (mmHg) 11 ± 5 16 ± 7 <0.001 
TPG (mmHg) 15 ± 5 11 ± 8 0.001 
SVR (dyne x s/cm5) 12 ± 7 91 ± 51 <0.001 
PVR (Wood) 535 ± 142 941 ± 355 <0.001 
CaO2 (ml/dl) 0.96 ± 0.44 1.44 ± 1.23 0.022  
CvO2 (ml/dl) 19.48 ± 1.68 16.74 ± 2.72 <0.001 
Ca-vO2 (ml/dl) 6.61 ± 1.46 8.06 ± 2.81 0.002  
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Table 5. Workload (wl) corrected hemodynamic variables associated with HFpEF during peak 
exercise. 
 
Univariable   
Multivariable 
Model 1  
(R2:0.87, p<0.0001) 
 
Multivariable 
Model 1  
(R2:0.94, p<0.0001) 
 
 
Coefficient p-value  Coefficient p-value Coefficient p-value 
Age (Y) 0.11 (0.07, 0.15) <0.0001    0.03 (-0.17, 0.22) 0.78 
BMI (kg/m2) 0.37 (0.24, 0.50) <0.0001    0.52 (0.02, 1.03) 0.04 
Heart rate/wl (bpm/watt) 6.7 (3.9, 9.5) <0.0001      
MAP/wl (mmHg/watt) 5.6 (3.3, 7.8) <0.0001      
SV/wl (ml/m2/watt) 4.8 (2.9, 6.8) <0.0001      
RAP/wl (mmHg/watt) 35.2 (20.2, 50.3) <0.0001      
PCWP/wl (mmHg/watt) 29.9 (11.3, 48.4) 0.002  28.0 (10.1, 45.8) 0.002 49.5 (0.2, 98.7) 0.049 
Ca-vO2/wl (ml/dl/watt) 36.9 (22.9, 50.9) <0.0001      
SVi/wl (ml/m2/watt) 9.0 (5.5, 12.5) <0.0001      
CO/wl (l/min/watt) 33.5 (19.3, 47.8) <0.0001      
CI/wl (l/min/m2/watt) 52.0 (29.5, 74.4) <0.0001      
mPAP/wl (mmHg/watt) 15.6 (8.5, 22.7) <0.0001      
TMP/wl (mmHg/watt) 28.6 (17.4, 39.8) <0.0001      
TPG/wl (mmHg/watt) 7.5 (3.6, 11.4) <0.0001      
SVR/wl (dyne x s/cm5/watt) 0.60 (0.36, 0.83) <0.0001      
PVR/wl (Wood/watt) 110.4 (58.3, 162.4) <0.0001      
 
Model 1: HR, MAP, SV, RAP, PCWP, and Ca-v02 were included in the model (all corrected for workload). 
Model 2: HR, MAP, SV, RAP, PCWP, and Ca-v02 (Model 1), adjusted for BMI and age. 
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Table 6. Comparison of the study design and findings in selected studies investigating exercise 
limitation and HFpEF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Wolsk et al. 
(current study) 
Reddy et al.(4) 
(JACC HF 2018) 
Obokata et al.(5) 
(EHJ 2018) 
Abudiab et 
al.(EJHF 2013) 
Haykowsky et al. 
(JACC 2011) 
Borlaug et al. 
(Circ 2006) 
Year of inclusion 
2013-2016 2000-2014 2011-2013 2002-2011 1998 2003-2005 
Enrollment Prospective Retrospective Retrospective Retrospective Retrospective Prospective 
HFpEF diagnosis established 
Invasive Invasive Invasive 
Clinical 
assessment 
Clinical 
assessment 
Invasive 
HFpEF patients (n) 108 134 50 109 59 17 
Healthy controls (n) 42 - - - 28 - 
Exercise protocol  
(HFpEF vs. controls) 
Peak vs. matched 
/ peak vs. peak 
Peak vs. peak Peak vs. peak / 
submax vs. 
submax. 
Peak vs. peak Peak vs. peak Peak vs. peak / 
submax vs. 
submax. 
Invasive measurements  Yes Yes Yes 65% of cases No No 
VO2 max test performed + + + + + + 
Primary novel findings Differences in 
PCWP and SV 
explain majority 
of difference 
between HFpEF 
and healthy 
controls at same 
workload (peak 
vs. matched) 
PCWP was 
independently 
correlated with 
exercise capacity 
within HFpEF 
patients 
Dynamic changes 
in PCWP and 
pulmonary 
function were 
interrelated and 
associated with 
symptoms of 
dyspnea in HFpEF 
patients 
Cardiac output 
relative to VO2 
was lower in 
HFpEF patients 
compared to 
patient with non-
cardiac dyspnea 
Both cardiac 
output and 
arterial-venous 
oxygen content 
differences 
contribute to the 
exercise 
intolerance in 
HFpEF patients 
HFpEF patients 
have reduced 
chronotropic, 
vasodilator, and 
cardiac output 
reserve during 
exercise 
compared with 
matched subjects  
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Figure 1. Changes in hemodynamic variables from baseline to peak exercise in HFpEF compared to 
controls at matched workloads. 
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Figure 2. The contribution of independent variables associated with HFpEF during exercise at 
matched workloads 
 
The contribution of each independent variable to the difference between HFpEF and controls at 
matched exercise is shown. The first column depicts the contribution of hemodynamic variables 
only. The second column depicts the contribution of hemodynamic + other independent variables 
identified. 
 
